Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
858 results about "L1" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
L1, also known as L1CAM, is a transmembrane protein member of the L1 protein family, encoded by the L1CAM gene. This protein, of 200-220 kDa, is a neuronal cell adhesion molecule with a strong implication in cell migration, adhesion, neurite outgrowth, myelination and neuronal differentiation. It also plays a key role in treatment-resistant cancers due to its function. It was first identified in 1984 by M. Schachner who found the protein in post-mitotic mice neurons.
Anti-PD-L1 antibodies, compositions and articles of manufacture
The present application relates to anti-PD-L1 antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.
Owner:F HOFFMANN LA ROCHE & CO AG
PD-1 Antibodies and PD-L1 Antibodies and Uses Thereof
ActiveUS20120039906A1Reduced activityStrong cytotoxicityAntibacterial agentsAnimal cellsPD-L1Antibody
Owner:INST JEAN PAOLI & IRENE CALMETTES +2
Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
ActiveUS20130309250A1Reduces and suppresses signalingReliable responseImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsAntigenTissue sample
The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1 / PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.
Owner:BRISTOL MYERS SQUIBB CO
Pd-1 binding proteins
ActiveUS20110008369A1Enhance host anti-microbial immunityImprove immunityAntibody mimetics/scaffoldsImmunoglobulins against animals/humansPD-L1Host immunity
The present invention features PD-1 binding proteins, a subset of which inhibits binding of PD-L1 to the PD-1 receptor. These binding proteins can be employed to modulate the immune system through the manipulation of the PD-1 signaling pathway, enhancing host immunity to treat infections and cancer.
Owner:MERCK SHARP & DOHME LLC
Methods of using Anti-pd-l1 antibodies and their use to enhance t-cell function to treat tumor immunity
InactiveUS20130045201A1Antibacterial agentsOrganic active ingredientsDiseaseAntiendomysial antibodies
The present application relates to methods of using anti-PD-L1 antibodies to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.
Owner:GENENTECH INC
PD-1 antibodies and PD-L1 antibodies and uses thereof
ActiveUS8741295B2Improve binding affinity and other biological propertyReduced activityAntibacterial agentsAntimycoticsPD-L1Antibody
Owner:INST JEAN PAOLI & IRENE CALMETTES +2
Targeted TGFβ inhibitors
ActiveUS9676863B2Effective therapyNervous disorderPeptide/protein ingredientsAntigenAntigen Binding Fragment
This invention relates generally to bifunctional molecules including (a) a TGFβRII or fragment thereof capable of binding TGFβ and (b) an antibody, or antigen binding fragment thereof, that binds to an immune checkpoint protein, such as Programmed Death Ligand 1 (PD-L1), uses of such molecules (e.g., for treating cancer), and methods of making such molecules.
Owner:MERCK PATENT GMBH
Method of cloning reproductive and respiratory syndrome resisting pig
Owner:CHINA AGRI UNIV
PD-L1 Antibodies and Uses Thereof
ActiveUS20150346208A1Biological material analysisImmunoglobulins against cell receptors/antigens/surface-determinantsAntigen Binding FragmentPD-L1
Provided herein are novel PD-L1 antibodies and methods for using the same for diagnosing a medical condition associated with elevated PD-L1 levels (e.g., cancer) in subjects in need thereof and antigen binding fragments thereof. The PD-L1 antibodies and antigen binding fragments are also useful in evaluating the efficacy of a particular therapeutic regime in a subject diagnosed as having a PD-L1-related medical condition.
Owner:VENTANA MEDICAL SYST INC
Anti-PD-L1 antibodies and uses thereof
ActiveUS9624298B2Function increaseUpregulate cell-mediated immune responsesNervous disorderPeptide/protein ingredientsAntigen Binding FragmentPD-L1
The present application relates to anti-PD-L1 antibodies or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, for the treatment of and cancer.
Owner:MERCK PATENT GMBH
CD47 and PD-L1 targeting bifunctional fusion protein
ActiveCN107459578AImprove targetingHigh activityPolypeptide with localisation/targeting motifAntibody mimetics/scaffoldsDisulfide bondingBlood safety
The invention relates to a CD47 and PD-L1 targeting bifunctional fusion protein, belongs to the field of biomedicine, and solves the problems that anti-PD-1 / PD-L1 treatment is poor in a low-immunogenicity tumor treatment effect and anti-CD47 treatment is poor in a targeting ability. The fusion protein is composed of a CD47 binding part and a PD-L1 binding part which are linked by a disulfide bond, can block the binding of CD47 and SIRPalpha, can block the binding of PD-L1 and PD-1, can achieve the effects of activating macrophages to phagocytize tumor cells and promoting antigen presentation in natural immunity, can achieve an effect of promoting the activation of tumor specific T cells in acquired immunity, and has lower blood toxicity; and as compared with the single use of anti-PD-L1 or anti-CD47 for treatment, the fusion protein has better antitumor curative effects and blood safety.
Owner:TAIZHOU MABTECH PHARM CO LTD
Mixed Virus-like particles
The present invention relates to mixed VLPs, and to a process for the production of a mixed VLP, the VLPs comprising L1 proteins from at least 2 different types of human papillomavirus.
Owner:GLAXOSMITHKLINE BIOLOGICALS SA
Humanized PD-L1 tumor cell line, animal model with same and application of humanized PD-L1 tumor cell line and animal model
ActiveCN105950560ASpeed up the processLethalCompounds screening/testingCell receptors/surface-antigens/surface-determinantsPD-L1Wilms' tumor
The invention provides a humanized PD-L1 tumor cell line MC-38-hPD-L1, a builtanimal tumor model with the same and a method for constructing the humanized PD-L1 tumor cell line. The method particularly includes knocking out animal-origin PD-L1 by the aid of CRISPR-CAS9; carrying out amplification and cultivation to obtain knocked-out cell banks; extracting DNA (deoxyribonucleic acid) and carrying out PCR (polymerase chain reaction) amplification; recycling and cloning amplification products; carrying out over-expression on human-origin PD-L1 in MC-38 cell lines of mPD-L1 KO by the aid of lentivirus systems; packaging lentivirus and screening Puromycin to obtain the humanized MC-38 cell line of PD-L1. The humanized PD-L1 tumor cell line, the animal tumor model and the method have the advantages that as shown by results, high killing efficiency and multiplication capacity are obviously presented by tumor infiltration CD8 T lymphocytes after antibody treatment is carried out, tumor infiltration Treg cells can be obviously inhibited after antibody treatment is carried out, and accordingly the method is proved to be effective and feasible from the aspect of molecular mechanisms.
Owner:SUZHOU INST OF SYST MEDICINE
Anti-pd-l1 combinations for treating tumors
InactiveUS20170114137A1Immunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsCombined Modality TherapyPD-L1
The present invention relates to therapeutic combinations and methods for treating cancers using combination therapy.
Owner:BIRDIE BIOPHARM INC
Anti-human PD-1 humanized monoclonal antibody and application thereof
ActiveCN106008714AStrong specificityHigh affinityAntibacterial agentsAntibody mimetics/scaffoldsMonoclonal antibodyPD-L1
The invention relates to the field of biological medicine and particularly relates to an anti-human PD-1 humanized monoclonal antibody and application thereof. By virtue of sieving, the anti-human PD-1 humanized monoclonal antibody with favorable specificity and relatively high compatibility and stability is obtained, can be specifically combined with human PD-1, but is not combined with other members of the CD28 family, is capable of blocking combination of PD-L1 and PD-1 and partially restoring functions of T cells, and has an obvious inhibiting effect on tumor growth.
Owner:REYOUNG SUZHOU BIOLOGY SCI & TECH CO LTD
Fusion protein containing fluorescent protein fragment and application of fusion protein
The invention relates to fusion protein containing a fluorescent protein fragment and an application of the fusion protein. Specifically, the invention provides the fusion protein, and the fusion protein has a structure as shown in (P1-L1)s-A1-(X)n-A2-(L2-P2)t. (X)n or A1-(X)n in the fusion protein can promote the folding and expression of fusion target peptide, improve the solubility of the fusion protein and reduce the intermolecular interaction of the fusion protein, so that the fusion target peptide can be folded under the high concentration with commercial significance. (X)n or A1-(X)n inthe fusion protein can be digested into a plurality of oligopeptides of which the lengths are far less than the length of the target peptide, so that the separation of the oligopeptides from the target peptide is better facilitated, and the purification of the target peptide is more convenient.
Owner:NINGBO KUNPENG BIOTECH CO LTD
Method of increasing yield of human papilloma virus L1 albumen pronucleus expression
ActiveCN101016542ALow costHigh expressionViral antigen ingredientsAntiviralsTGE VACCINENucleic acid sequence
The invention discloses a method to increase human papilloma virus L1 protein pronucleus expression productivity and also discloses a encode HPV L1 protein codon majorizing nucleic acid sequence from this method, which is characterized by the following: supplying expression carrier and host cell and HPVL1 protein poly body of nucleic acid sequence; disclosing appliance in preparing vaccine, drug compound and immunodiagnosis or antibody. The nucleic acid sequence expressing quantity possesses distinctive improvement, which decreases the preparing cost effectively.
Owner:BEIJING HEALTH GUARD BIOTECH
Preparation method and application of humanized gene modification animal model
ActiveCN107815466AReduce development riskSpeed up the R&D processCell receptors/surface-antigens/surface-determinantsSugar derivativesPD-L1Gene Modification
The invention relates to a humanized gene genetically modified non-human animal, particularly a genetically modified rodent, especially a genetically modified mouse, and in particular relates to a construction method of a humanized PD-L1 gene animal model and application of the model in the biomedicine field.
Owner:BIOCYTOGEN JIANGSU CO LTD +1
Anti-PD-L1 antibody as well as pharmaceutical composition and application of anti-PD-L1 antibody
ActiveCN106699891ABinding blockRelief of immunosuppressionBiological material analysisImmunoglobulins against cell receptors/antigens/surface-determinantsAntigenMolecular Immunology
The invention belongs to the field of oncotherapy and molecular immunology, and relates to an anti-PD-L1 antibody as well as a pharmaceutical composition and an application of the anti-PD-L1 antibody. Particularly, the invention relates to a monoclonal antibody or an antigen binding fragment of the monoclonal antibody, wherein a heavy chain variable region of the monoclonal antibody comprises a CDR, the amino acid sequence of the CDR is SEQ ID NO:1-3, and / or a light chain variable region of the monoclonal antibody comprises a CDR, and the amino acid sequence of the CDR is SEQ ID NO:4-6. The monoclonal antibody is specifically bound with PD-L1 well, specifically relieves immunosuppression of PD-1 on the organism, and activates the T iymphocyte.
Owner:BEIJING MABWORKS BIOTECH
Shorten human papilloma virus 16 type L1 protein
Owner:XIAMEN INNOVAX BIOTECH +1
Detection and identification of human papillomavirus by PCR and type-specific reverse hybridization
InactiveUS20030165821A1Rapid and reliable for detectionMicrobiological testing/measurementFermentationHuman papillomavirusType specific
A method for detection and / or identification of HPV present in a biological sample comprising amplification of HPV polynucleic acids and of hybridization of said amplified polynucleic acids to a number of probes whereby a short fragment of the L1 gene of HPV is amplified after which, the amplimers are contacted with probes that specifically hybridize to the said short fragment of the L1 gene of at least one HPV type and a diagnostic kit to perform said method and primers and probes used in the said method.
Owner:INNOGENETICS NV
Anti-PD-L1 nano antibody and coding sequence, preparation method and application thereof
ActiveCN109265548AHigh detection sensitivityBiological material analysisImmunoglobulins against cell receptors/antigens/surface-determinantsEscherichia coliPD-L1
The invention discloses an anti-PD-L1 nano antibody and a coding sequence, a preparation method and application thereof. An amino acid sequence of an antibody VHH chain is as shown in SEQ ID NO:2, SEQID NO:11 or SEQ ID NO:20. Compared with the prior art, the anti-PD-L1 nano antibody has the following advantages: (1) the anti-PD-L1 nano antibody has high specificity, and high detection sensitivity; and (2) the antibody can be efficiently expressed in escherichia coli, so a foundation is provided for follow-up mass production of an immunoreagent and a tumor drug composition.
Owner:JIANGSU TARGET BIOMEDICINE RES INST
PD-L1 IgV affinity peptide with antineoplastic activity, and preparation method and application of thereof
ActiveCN104098651AHas antitumor activityGood antitumor activityPeptide/protein ingredientsPeptide preparation methodsBULK ACTIVE INGREDIENTAnti neoplastic
The invention belongs to the technical field of biopharmacy, particularly relates to a PD-L1 IgV targeted affinity peptide product with antineoplastic activity, and a preparation method and application of the affinity peptide product. According to the invention, the affinity peptide is specifically bonded in the PD-L1 IgV area, the amino acid sequence of the affinity peptide is ANGSRLV (Ala-Asn-Gly-Ser-Arg-Leu-Val), and the molecular weight of the affinity peptide is 715.4; the affinity peptide can be artificially synthesized by adopting the Fomc solid-phase polypeptide synthesis, and can be adopted as the mainly active ingredient in preparing colon cancer (CT26) resistance medicines. Bacteriophages are adopted to display the peptide bank screening technique, the PD-L1 IgV is adopted as the target for high-flux screening, and the affinity peptide with the antineoplastic activity is artificially synthesized; the inventor further proves that the affinity peptide has the better antineoplastic activity, can remarkably inhibit growth of tumors in rats, and provides the novel thinking and theoretical basis for the research and development of PD-L1-based medicines.
Owner:ZHENGZHOU UNIV
Broad spectrum monoclonal antibodies or antigen binding fragments thereof of anti-HPV L1 protein, and applications thereof
ActiveCN103483447AAdvantage detectionPredominant diagnosisFungiBacteriaAntigen Binding FragmentAntigen binding
The invention relates to monoclonal antibodies and antigen binding fragments thereof, which can have a broad spectrum combination with human papilloma virus (HPV) L1 protein, coding of the sequences of the monoclonal antibodies and the antigen binding fragments thereof, generation of cell strains of the monoclonal antibodies and the antigen binding fragments thereof, and methods and applications of the monoclonal antibodies and the antigen binding fragments thereof on diagnosis, prevention or treatment.
Owner:XIAMEN UNIV +1
Human papilloma virus genes, vector, strain, and expression method thereof
ActiveCN104513826AImprove translationPromote research and developmentFungiViral antigen ingredientsPichia pastorisHuman Papillomavirus Major Capsid Protein L1
The present invention relates to genes of the Pichia pastoris expression codon-optimized main capsid protein L1 of human papilloma virus types 52,31 and 45, a vector containing the genes, a strain, a preparation method, and an expression method thereof.
Owner:SHANGHAI ZERUN BIOTECHNOLOGY CO LTD
Monoclonal antibody against PD-1, and preparation method and application thereof
InactiveCN108341871AImprove biological activityEffective combinationImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsDiseasePD-L1 Positive
The invention specifically discloses a monoclonal antibody against human PD-1, and a preparation method and application thereof, belonging to the field of antibodies. The monoclonal antibody against human PD-1 in the invention has good biological activity, and can effectively bind to the extracellular region of a human PD-1 protein receptor, block PD-1 protein at a protein level and a cellular level, prevent binding of the PD- 1 protein to ligand PD-L1 and enhances immunity. The monoclonal antibody can be individually used or used in combination with other anti-tumor drugs for tumor immunotherapy and the diagnosis and screening of patients with PD-L1 positive tumors, and has good prospects in preparation of drugs for treating tumors, anti-autoimmune diseases and the like.
Owner:SUNSHINE GUOJIAN PHARMA (SHANGHAI) CO LTD
Human papillomavirus shell protein L1 short peptide and application thereof
InactiveCN101186636ASerum immunoglobulinsImmunoglobulins against cell receptors/antigens/surface-determinantsAlphapapillomavirusCoat protein
The invention relates to a polypeptide, in particular to a human papilloma virus coat protein L1 short peptide and relative application. The invention is characterized in that the sequence of the human papilloma virus coat protein L1 short peptide is N-EVNLKEKFSADLDQFPLGRKFLLQAGLKAK-C. The invention can simultaneously induce human papilloma virus coat protein L1 short peptide with immunity reaction on high risk type and low risk type, which can induce and form the antibody for various human papilloma virus (HPV) and coat protein (HPV L1), to check various HPV or HPV L1, while the antibody can be used in biological pharmaceutical engineering, to purify and prepare various HPV or HPV L1.
Owner:CHINA THREE GORGES UNIV
Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue
InactiveUS20160084839A1Improve standardizationAntibody ingredientsDisease diagnosisProgrammed deathPD-L1
The present disclosure provides processes for describing and quantifying the expression of human programmed death ligand-1 (PD-L1) in tumor tissue sections as detected by immunohistochemical assay using an antibody that specifically binds to PD-L1. The results generated using these processes have a variety of experimental, diagnostic and prognostic applications.
Owner:MERCK SHARP & DOHME CORP
PD-L1IgV-targeting affinity peptide D1 with anti-tumor activity
ActiveCN103936835AGood antitumor activityInhibit growthPeptide/protein ingredientsPeptide preparation methodsBULK ACTIVE INGREDIENTHigh-throughput screening
The invention belongs to the technical field of bio-pharmacy and specifically relates to a PD-L1IgV-targeting D-configuration affinity peptide D1 product with anti-tumor activity, as well as preparation and application thereof. The affinity peptide D1 is specifically bound to a PD-L1IgV region, the amino acid sequence is NYSKPTDRQYHF, and the molecular weight is 1554.7. The affinity peptide D1 is prepared through a Fomc solid-phase polypeptide synthesis method, and plays a role in preparation of anti-colon cancer medicaments as a main active ingredient. The affinity peptide D1 provided by the invention is obtained by utilizing a mirroring bacteriophage display peptide library screening technology and performing high-throughput screening by taking PD-L1IgV as a target point. Through tumor-bearing experiments in mouse bodies, the inventor proves that the affinity peptide D1 has better anti-tumor activity and can obviously inhibit the growth of tumors in the mouse bodies, so that a new idea and theoretical basis are provided for researching and developing PD-L1-based medicaments.
Owner:ZHENGZHOU UNIV
PD-L1 IgV affinity peptide S10 with antitumor activity
ActiveCN104086627AGood antitumor activityInhibit growthPeptide/protein ingredientsPeptide preparation methodsPharmacyColon carcinoma
The invention belongs to the technical field of biological pharmacy, and concretely relates to a PD-L1 IgV affinity peptide S10 product with antitumor activity, and preparation and application thereof. The affinity peptide S10 is specifically bond at PD-l1 IgV region, has the amino acid sequence of WSHGGHQHFIRF, and has the molecular weight of 1507.7. The affinity peptide S10 is prepared through a Fomc solid-phase peptide synthesis method, and plays a role as a main active composition for preparing anti-colorectal carcinoma medicines. The provided affinity peptide S10 is obtained by utilizing a phage-display peptide-library screening technology and taking PD-L1 IgV as a target for performing high-flux screening. Experiments of bearing a cancer in a mouse prove that affinity peptide S10 has relatively good antitumor activity, is capable of obviously inhibiting growth of tumor in a mouse, and provides new thinking and theoretical base for research and exploitation of medicines based on PD-L1.
Owner:ZHENGZHOU UNIV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com